Company registration number 12211790 (England and Wales)
Datar Cancer Genetics UK Private Limited
Audited Financial Statements
For the year ended
31 March 2024
Pages for filing with registrar
Datar Cancer Genetics UK Private Limited
Contents
Page
Statement of financial position
1
Notes to the financial statements
2 - 6
Datar Cancer Genetics UK Private Limited
Statement Of Financial Position
As at 31 March 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
4
775,931
649,806
Current assets
Debtors
5
1,717,523
586,496
Cash at bank and in hand
53,925
75,455
1,771,448
661,951
Creditors: amounts falling due within one year
6
(954,318)
(1,863,576)
Net current assets/(liabilities)
817,130
(1,201,625)
Net assets/(liabilities)
1,593,061
(551,819)
Capital and reserves
Called up share capital
1,234,842
641,100
Share premium account
901,986
-
0
Profit and loss reserves
(543,767)
(1,192,919)
Total equity
1,593,061
(551,819)

The notes on pages 2 to 6 form part of these financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the income statement within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 28 March 2025 and are signed on its behalf by:
S.S. Deshpande
Director
Company registration number 12211790 (England and Wales)
Datar Cancer Genetics UK Private Limited
Notes To The Financial Statements
For the year ended 31 March 2024
- 2 -
1
General information

Datar Cancer Genetics UK Private Limited is a private company limited by shares incorporated in England and Wales. The registered office is 2-4 Frederick Sanger Road, Surrey Research Park, Guildford, Surrey, United Kingdom, GU2 7YD.

2
Accounting policies
2.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

2.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. During the year a loan of £1,465,728 due to the company's parent undertaking was converted into ordinary share capital. The directors believe that ongoing financial support from the parent company is no longer required.

 

During the year, the directors carried out a comprehensive assessment of the company's budgets and cash flow forecasts for the foreseeable future, including sensitivity analysis of cash flow forecast based on three different scenarios – neutral, the best and the worst. Based on that, the directors believe that the company is able to generate sufficient working capital from its own operations to meet all its obligations as they fall due. Consequently, the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

2.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for cancer research and screening services provided in the normal course of business.

 

Revenue from contracts for the provision of services is recognised by the company either at the point in which a sample is received or at the point in time the report is issued to the customer and this is determined in reference to the specific terms agreed with each customer. In the event that a test is cancelled by a customer, the company recognises a proportion of the revenue for that contract. This is based on the time elapsed from receipt of a sample and is in line with the terms agreed with the customer.

2.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold improvements
straight line over lease term
Plant and machinery
20% straight line
Equipment
33% straight line
Datar Cancer Genetics UK Private Limited
Notes To The Financial Statements (Continued)
For the year ended 31 March 2024
2
Accounting policies
(Continued)
- 3 -

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

2.5
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

2.6
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand.

2.7
Financial instruments

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

 

Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price.

Basic financial liabilities

Basic financial liabilities are initially recognised at transaction price.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price.

2.8
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Datar Cancer Genetics UK Private Limited
Notes To The Financial Statements (Continued)
For the year ended 31 March 2024
2
Accounting policies
(Continued)
- 4 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

2.9
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense.

2.10
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2.11
Share-based payments

Equity-settled share-based payments are measured at the fair value of the services received.

2.12
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
29
23
Datar Cancer Genetics UK Private Limited
Notes To The Financial Statements (Continued)
For the year ended 31 March 2024
- 5 -
4
Tangible fixed assets
Leasehold improvements
Plant and machinery
Equipment
Total
£
£
£
£
Cost
At 1 April 2023
159,844
803,392
33,576
996,812
Additions
924
382,315
17,126
400,365
At 31 March 2024
160,768
1,185,707
50,702
1,397,177
Depreciation and impairment
At 1 April 2023
83,068
242,423
21,515
347,006
Depreciation charged in the year
37,607
222,903
13,730
274,240
At 31 March 2024
120,675
465,326
35,245
621,246
Carrying amount
At 31 March 2024
40,093
720,381
15,457
775,931
At 31 March 2023
76,776
560,969
12,061
649,806
5
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
1,161,525
466,722
Amounts owed by group undertakings
276,964
26,481
Other debtors
78,046
93,293
1,516,535
586,496
2024
2023
Amounts falling due after more than one year:
£
£
Deferred tax asset
200,988
-
0
Total debtors
1,717,523
586,496
Datar Cancer Genetics UK Private Limited
Notes To The Financial Statements (Continued)
For the year ended 31 March 2024
- 6 -
6
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
297,067
200,178
Amounts owed to group undertakings
255,163
1,533,515
Taxation and social security
41,873
32,523
Other creditors
360,215
97,360
954,318
1,863,576
7
Operating lease commitments

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2024
2023
£
£
594,295
475,618
8
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

Opinion

In our opinion the financial statements:

Senior Statutory Auditor:
Izabela Kuchmacz ACA
Statutory Auditor:
Ward Williams
Date of audit report:
28 March 2025
9
Parent company

The parent company is Blue Leopard Genomics Essentials Private Limited, incorporated in India with registered office at F-8 D Road MIDC, Ambad, Nashik, India, 4220105. Datar Cancer Genetics Ltd is the parent of the smallest group for which consolidated accounts including Datar Cancer Genetics UK Private Limited are drawn up, and copies of these accounts can be obtained from its registered office at F-8 D Road MIDC, Ambad, Nashik, India, 4220105.

2024-03-312023-04-01falsefalsefalse28 March 2025CCH SoftwareCCH Accounts Production 2024.300No description of principal activityS.R. DatarS.S. DeshpandeS. SchusterV. DattaR.B. Datar122117902023-04-012024-03-31122117902024-03-31122117902023-03-3112211790core:LeaseholdImprovements2024-03-3112211790core:PlantMachinery2024-03-3112211790core:ComputerEquipment2024-03-3112211790core:LeaseholdImprovements2023-03-3112211790core:PlantMachinery2023-03-3112211790core:ComputerEquipment2023-03-3112211790core:CurrentFinancialInstrumentscore:WithinOneYear2024-03-3112211790core:CurrentFinancialInstrumentscore:WithinOneYear2023-03-3112211790core:CurrentFinancialInstruments2024-03-3112211790core:CurrentFinancialInstruments2023-03-3112211790core:ShareCapital2024-03-3112211790core:ShareCapital2023-03-3112211790core:SharePremium2024-03-3112211790core:SharePremium2023-03-3112211790core:RetainedEarningsAccumulatedLosses2024-03-3112211790core:RetainedEarningsAccumulatedLosses2023-03-3112211790bus:Director22023-04-012024-03-3112211790core:LeaseholdImprovements2023-04-012024-03-3112211790core:PlantMachinery2023-04-012024-03-3112211790core:ComputerEquipment2023-04-012024-03-31122117902022-04-012023-03-3112211790core:LeaseholdImprovements2023-03-3112211790core:PlantMachinery2023-03-3112211790core:ComputerEquipment2023-03-31122117902023-03-3112211790core:WithinOneYear2024-03-3112211790core:WithinOneYear2023-03-3112211790core:AfterOneYear2024-03-3112211790core:AfterOneYear2023-03-3112211790bus:PrivateLimitedCompanyLtd2023-04-012024-03-3112211790bus:SmallCompaniesRegimeForAccounts2023-04-012024-03-3112211790bus:FRS1022023-04-012024-03-3112211790bus:Audited2023-04-012024-03-3112211790bus:Director12023-04-012024-03-3112211790bus:Director32023-04-012024-03-3112211790bus:Director42023-04-012024-03-3112211790bus:Director52023-04-012024-03-3112211790bus:FullAccounts2023-04-012024-03-31xbrli:purexbrli:sharesiso4217:GBP